Cargando…

Objective validation of central sensitization in the rat UVB and heat rekindling model

BACKGROUND: The UVB and heat rekindling (UVB/HR) model shows potential as a translatable inflammatory pain model. However, the occurrence of central sensitization in this model, a fundamental mechanism underlying chronic pain, has been debated. Face, construct and predictive validity are key requisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Weerasinghe, NS, Lumb, BM, Apps, R, Koutsikou, S, Murrell, JC
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232048/
https://www.ncbi.nlm.nih.gov/pubmed/24590815
http://dx.doi.org/10.1002/j.1532-2149.2014.00469.x
_version_ 1782344519946076160
author Weerasinghe, NS
Lumb, BM
Apps, R
Koutsikou, S
Murrell, JC
author_facet Weerasinghe, NS
Lumb, BM
Apps, R
Koutsikou, S
Murrell, JC
author_sort Weerasinghe, NS
collection PubMed
description BACKGROUND: The UVB and heat rekindling (UVB/HR) model shows potential as a translatable inflammatory pain model. However, the occurrence of central sensitization in this model, a fundamental mechanism underlying chronic pain, has been debated. Face, construct and predictive validity are key requisites of animal models; electromyogram (EMG) recordings were utilized to objectively demonstrate validity of the rat UVB/HR model. METHODS: The UVB/HR model was induced on the heel of the hind paw under anaesthesia. Mechanical withdrawal thresholds (MWTs) were obtained from biceps femoris EMG responses to a gradually increasing pinch at the mid hind paw region under alfaxalone anaesthesia, 96 h after UVB irradiation. MWT was compared between UVB/HR and SHAM-treated rats (anaesthetic only). Underlying central mechanisms in the model were pharmacologically validated by MWT measurement following intrathecal N-methyl-d-aspartate (NMDA) receptor antagonist, MK-801, or saline. RESULTS: Secondary hyperalgesia was confirmed by a significantly lower pre-drug MWT {mean [±standard error of the mean (SEM)]} in UVB/HR [56.3 (±2.1) g/mm(2), n = 15] compared with SHAM-treated rats [69.3 (±2.9) g/mm(2), n = 8], confirming face validity of the model. Predictive validity was demonstrated by the attenuation of secondary hyperalgesia by MK-801, where mean (±SEM) MWT was significantly higher [77.2 (±5.9) g/mm(2) n = 7] in comparison with pre-drug [57.8 (±3.5) g/mm(2) n = 7] and saline [57.0 (±3.2) g/mm(2) n = 8] at peak drug effect. The occurrence of central sensitization confirmed construct validity of the UVB/HR model. CONCLUSIONS: This study used objective outcome measures of secondary hyperalgesia to validate the rat UVB/HR model as a translational model of inflammatory pain. WHAT'S ALREADY KNOWN ABOUT THIS TOPIC? Most current animal chronic pain models lack translatability to human subjects. Primary hyperalgesia is an established feature of the UVB/heat rekindling inflammatory pain model in rodents and humans, but the presence of secondary hyperalgesia, a hallmark feature of central sensitization and thus chronic pain, is contentious. WHAT DOES THIS STUDY ADD? Secondary hyperalgesia was demonstrated in the rat UVB/heat rekindling model using an objective outcome measure (electromyogram), overcoming the subjective limitations of previous behavioural studies.
format Online
Article
Text
id pubmed-4232048
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42320482014-12-15 Objective validation of central sensitization in the rat UVB and heat rekindling model Weerasinghe, NS Lumb, BM Apps, R Koutsikou, S Murrell, JC Eur J Pain New Research BACKGROUND: The UVB and heat rekindling (UVB/HR) model shows potential as a translatable inflammatory pain model. However, the occurrence of central sensitization in this model, a fundamental mechanism underlying chronic pain, has been debated. Face, construct and predictive validity are key requisites of animal models; electromyogram (EMG) recordings were utilized to objectively demonstrate validity of the rat UVB/HR model. METHODS: The UVB/HR model was induced on the heel of the hind paw under anaesthesia. Mechanical withdrawal thresholds (MWTs) were obtained from biceps femoris EMG responses to a gradually increasing pinch at the mid hind paw region under alfaxalone anaesthesia, 96 h after UVB irradiation. MWT was compared between UVB/HR and SHAM-treated rats (anaesthetic only). Underlying central mechanisms in the model were pharmacologically validated by MWT measurement following intrathecal N-methyl-d-aspartate (NMDA) receptor antagonist, MK-801, or saline. RESULTS: Secondary hyperalgesia was confirmed by a significantly lower pre-drug MWT {mean [±standard error of the mean (SEM)]} in UVB/HR [56.3 (±2.1) g/mm(2), n = 15] compared with SHAM-treated rats [69.3 (±2.9) g/mm(2), n = 8], confirming face validity of the model. Predictive validity was demonstrated by the attenuation of secondary hyperalgesia by MK-801, where mean (±SEM) MWT was significantly higher [77.2 (±5.9) g/mm(2) n = 7] in comparison with pre-drug [57.8 (±3.5) g/mm(2) n = 7] and saline [57.0 (±3.2) g/mm(2) n = 8] at peak drug effect. The occurrence of central sensitization confirmed construct validity of the UVB/HR model. CONCLUSIONS: This study used objective outcome measures of secondary hyperalgesia to validate the rat UVB/HR model as a translational model of inflammatory pain. WHAT'S ALREADY KNOWN ABOUT THIS TOPIC? Most current animal chronic pain models lack translatability to human subjects. Primary hyperalgesia is an established feature of the UVB/heat rekindling inflammatory pain model in rodents and humans, but the presence of secondary hyperalgesia, a hallmark feature of central sensitization and thus chronic pain, is contentious. WHAT DOES THIS STUDY ADD? Secondary hyperalgesia was demonstrated in the rat UVB/heat rekindling model using an objective outcome measure (electromyogram), overcoming the subjective limitations of previous behavioural studies. BlackWell Publishing Ltd 2014-09 2014-03-03 /pmc/articles/PMC4232048/ /pubmed/24590815 http://dx.doi.org/10.1002/j.1532-2149.2014.00469.x Text en Copyright © 2014 European Pain Federation - EFIC® http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle New Research
Weerasinghe, NS
Lumb, BM
Apps, R
Koutsikou, S
Murrell, JC
Objective validation of central sensitization in the rat UVB and heat rekindling model
title Objective validation of central sensitization in the rat UVB and heat rekindling model
title_full Objective validation of central sensitization in the rat UVB and heat rekindling model
title_fullStr Objective validation of central sensitization in the rat UVB and heat rekindling model
title_full_unstemmed Objective validation of central sensitization in the rat UVB and heat rekindling model
title_short Objective validation of central sensitization in the rat UVB and heat rekindling model
title_sort objective validation of central sensitization in the rat uvb and heat rekindling model
topic New Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232048/
https://www.ncbi.nlm.nih.gov/pubmed/24590815
http://dx.doi.org/10.1002/j.1532-2149.2014.00469.x
work_keys_str_mv AT weerasinghens objectivevalidationofcentralsensitizationintheratuvbandheatrekindlingmodel
AT lumbbm objectivevalidationofcentralsensitizationintheratuvbandheatrekindlingmodel
AT appsr objectivevalidationofcentralsensitizationintheratuvbandheatrekindlingmodel
AT koutsikous objectivevalidationofcentralsensitizationintheratuvbandheatrekindlingmodel
AT murrelljc objectivevalidationofcentralsensitizationintheratuvbandheatrekindlingmodel